Pfizer has selected a once-daily formulation of danuglipron, an oral GLP-1 receptor agonist, based on encouraging results from an ongoing pharmacokinetic study. The company aims to optimize dosing through studies in the second half of 2024 before initiating registration-enabling trials.
Pfizer emphasizes the importance of obesity as a therapeutic focus, with danuglipron being the most advanced candidate in its robust pipeline. Mikael Dolsten, Pfizer’s Chief Scientific Officer, believes that the once-daily formulation has the potential to provide a competitive edge in the GLP-1 space.
The ongoing study has assessed the pharmacokinetics and safety of immediate- and modified-release danuglipron formulations in healthy adults. Results indicate a once-daily dosing potential, with a favorable safety profile consistent with previous studies. No liver enzyme elevations have been observed in over 1,400 participants.
Danuglipron is an investigational medicine designed to regulate blood sugar levels by increasing insulin release. It may also slow digestion and enhance feelings of fullness after eating, potentially aiding in weight loss. However, it is essential to note that danuglipron is not currently approved by health authorities.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
